Cell Reports-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2020-12-07 ms4000000148246292

耶

134 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2020-03-06 wangzy930519_68981948

是的，5000美元153****8296 2020-03-05 发表::
请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表:
请问各位，该杂志版面费是5000美元＋嘛？

153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？

183 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2019-12-17 147d7137m03(暂无昵称)

审稿速度:2.0 | 投稿命中率:25.0
经验分享：allreviewcompleted等待编辑决定煎熬中

171 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2024-04-30 darktempler 来自江苏省

说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！

10 0

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2024-02-07 黑鬼儿来自河北省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：molecular biology
经验分享：难度不低，影响因子不高，不划算

33 0

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2024-01-22 ms2000001775137343 来自安徽省

6月投稿，今年1月接收，历时7个月

38 0

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2023-07-13 poiju 来自上海

偏重的研究方向：肿瘤
经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅

191 0

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2023-06-14 ms7000001335611101 来自天津

偏重的研究方向：医学;肿瘤
经验分享：请问under review是送审了吗？为什么没收到邮件呢

98 0

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2023-04-29 ms2000000147841561 来自河北省

好

103 0

[GetPortalCommentsPageByObjectIdResponse(id=905661, encodeId=aa2290566121, content=耶 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47205398653, createdName=ms4000000148246292, createdTime=Mon Dec 07 11:46:19 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586022, encodeId=6b03586022da, content=是的，5000美元153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？153****8296 2020-03-05 00:00:00 发表: 请问各位，该杂志版面费是5000美元＋嘛？, beContent=153****8296 2020-03-05 发表:: 请问各位，该杂志版面费是5000美元＋嘛？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05852426638, createdName=wangzy930519_68981948, createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2129298, encodeId=b2fe21292989b, content=好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Sat Apr 29 21:47:11 CST 2023, time=2023-04-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2124142, encodeId=6be1212414218, content=偏重的研究方向：肿瘤 经验分享：请问目前cell report投稿需要提交所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb538107486, createdName=ms5000001244389384, createdTime=Thu Apr 06 16:43:11 CST 2023, time=2023-04-06, status=1, ipAttribution=上海)]

2023-04-06 ms5000001244389384 来自上海

偏重的研究方向：肿瘤
经验分享：请问目前cell report投稿需要提交所有的原始数据吗

103 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务